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Abstract: 19 
Background: 20 
SARS-CoV-2 is a novel coronavirus first diagnosed in US hospitals in January 2020. Typical presenting 21 
symptoms include fever, dry cough, dyspnea, and hypoxia. However, several other symptoms have been 22 
reported, including fatigue, weakness, diarrhea, and abdominal pain. We have identified a series of 23 
patients with diabetic ketoacidosis (DKA) likely precipitated by COVID-19. 24 
Case Series:  25 
We describe five patients with previously known type 2 diabetes and no history of DKA, who presented 26 
to the emergency department with new-onset DKA and COVID-19.  27 
Why should an emergency physician be aware of this? 28 
Diabetes mellitus is a known risk factor for poor outcomes in viral respiratory illnesses, including 29 
COVID-19.  Infection may precipitate DKA in patients with type 2 diabetes. Aggressive management of 30 
these patients is recommended; however, management guidelines have not yet been put forth for this 31 
unique subset of patients. 32 
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Introduction: 40 
SARS-CoV-2 is a novel coronavirus first discovered in Wuhan, China, in late December 20191 41 
and first identified in the United States in mid-January 2020. Presenting symptoms vary but include fever, 42 
dry cough, fatigue, myalgias, abdominal pain, and diarrhea.1,2 Patients with advanced age and medical 43 
comorbidities are at higher risk for mortality, morbidity, and need for intensive care unit (ICU) 44 
admission.2,3 Cardiovascular disease and diabetes are associated with particularly high risk for death 45 
among patients with COVID-19.3  46 
Diabetic ketoacidosis (DKA) is a life-threatening condition seen most commonly in patients with 47 
type 1 diabetes mellitus (DM);4 however, physiologically stressful conditions such as surgery, trauma, or 48 
infection may precipitate DKA in type 2 diabetes mellitus (DM2), with approximately 30-50% of DKA 49 
cases triggered by infection.5 DKA confers a mortality rate of approximately 5%, but notably higher 50 
mortality rates occur in the elderly and patients with concurrent acute illnesses.5 The overall mortality in 51 
patients with COVID-19 is likely to be approximately 1-3%. However, among patients with diabetes, 52 
mortality may be over 7%, and likely higher in the elderly diabetic population.3,6 We are unaware of any 53 
reports of DKA among COVID-19 patients or the associated mortality risk. It is unknown whether the 54 
mortality of these two conditions is additive or even exponential. Given the high-risk nature of both DKA 55 
and COVID-19, it is paramount that DKA be quickly recognized in patients with concern for COVID-19 56 
and conversely that COVID-19 is considered as a precipitant for DKA.  57 
To our knowledge, there are no reported cases of new-onset DKA in patients with DM2 and 58 
COVID-19 infection. In this novel case series, we report five patients who presented to the emergency 59 
department (ED) with a spectrum of respiratory complaints and were found to be in DKA, likely 60 
precipitated by COVID-19.  61 
This case series was granted exempt status by the local Institutional Review Board. Table 1 62 
provides demographic and laboratory details for each patient. Figure 1 shows the chest x-ray findings of 63 
the presented cases. 64 
Case 1 65 
A 55-year old African-American male with DM2 was brought in from home for altered mental 66 
status and hypoxia. He reported a cough for several days prior, and on the day of presentation had become 67 
confused. His initial prehospital oxygen saturation was 35%. He was given oxygen via non-rebreather 68 
mask and brought to the ED, where he was persistently hypoxic to 66% and was subsequently intubated. 69 
Initial labs were consistent with DKA, and a chest x-ray showed bilateral pneumonia (Figure 1a).  He was 70 
started on a DKA protocol with an intravenous insulin drip and crystalloid fluid. He was started on 71 
antibiotics and hydroxychloroquine for presumed.COVID-19, which was confirmed by PCR testing on 72 
hospital day 2.   73 
Upon arrival to the ICU, the patient’s anion gap had closed, and he was transitioned to 74 
subcutaneous insulin. As of the time of manuscript completion, he is on hospital day 15, still intubated in 75 
the ICU, with slowly improving ventilator parameters. 76 
Case 2:  77 
A 57-year-old Hispanic female with a history of DM2 on glipizide and metformin presented to 78 
the ED with three days of increasing dyspnea associated with fevers and cough.  She had been evaluated 79 
in the ED 12 hours earlier with a chest radiograph, electrocardiogram, an unremarkable metabolic panel, 80 
and COVID-19 testing. She was discharged with a diagnosis of pneumonia. After discharge, her vomiting 81 
and dyspnea worsened, and she returned to the ED.   82 
Laboratory work-up at the second visit revealed laboratory abnormalities consistent with DKA 83 
(Table 1). She was tachycardic but normotensive, with tachypnea and moderate respiratory distress. She 84 
was started on an intravenous insulin drip and IV crystalloid fluids in addition to antibiotics and 85 
hydroxychloroquine for multifocal pneumonia. She was admitted to a medical ward, her anion gap closed, 86 
and she was transitioned to subcutaneous insulin before being discharged from the hospital. She tested 87 
positive for COVID-19 on hospital day 2. Upon follow up, she was doing well at home.  88 
Case 3:  89 
A 38-year-old Hispanic male with a past medical history of DM2 on insulin detemir and aspart 90 
presented to the ED for one day of vomiting associated with subjective fevers, cough, and shortness of 91 
breath. He noted his blood sugars had recently been elevated to over 300. Laboratory findings were 92 
consistent with DKA. His chest XRay showed with bilateral infiltrates.  93 
He was started on an intravenous insulin drip and given crystalloid fluids.  He was admitted to a 94 
medical ward where his anion gap resolved, and he was transitioned to a subcutaneous insulin regimen. 95 
He tested positive for COVID-19 on hospital day 2 and was discharged on hospital day 3. He has 96 
remained stable and recently was seen for follow up with improved glycemic control. 97 
Case 4: 98 
A 45-year-old Hispanic female with a history of DM2, non-adherent with medication, presented 99 
to the ED with concerns for COVID-19 after developing headache, myalgias, anorexia, and fever.  She 100 
had previously been managed with oral antihyperglycemics but had stopped taking her medications two 101 
months prior to presentation.  102 
  The patient was ill-appearing, with tachypnea and clinical dehydration. Initial laboratory 103 
findings showed DKA. She was admitted to a medical ward and treated with intravenous insulin and 104 
crystalloid fluids.  Her anion gap resolved after twelve hours, and she was transitioned to a subcutaneous 105 
insulin regimen. Her COVID-19 testing returned positive on hospital day two. She was discharged after 106 
two days and has not returned to the ED. 107 
Case 5: 108 
A 63-year-old African American female with a history of coronary artery disease, asthma, 109 
hypertension, and insulin-dependent DM2 presented with dyspnea and cough for one week. She was 110 
severely tachypneic on arrival with a respiratory rate of 53 breaths per minute and an oxygen saturation of 111 
95% on 6 Liters of oxygen via nasal cannula. A chest x-ray showed bilateral pulmonary infiltrates (Figure 112 
1e). Given the respiratory distress and bilateral pneumonia, the patient was started on antimicrobial 113 
coverage as well as hydroxychloroquine, and swabbed for COVID-19, which returned positive on 114 
hospital day 2.  115 
Initial laboratory studies (Table 1) were consistent with DKA. She was intubated for refractory 116 
hypoxia. Despite attempts to match her intrinsically high minute ventilation, the patient’s acidosis 117 
continued to worsen, resulting in near cardiac arrest several hours later with severe hemodynamic 118 
instability. She received bicarbonate with improvement of circulation and perfusion. Although the 119 
patient’s anion gap closed and DKA resolved, she developed worsening multi-organ system failure 120 
despite maximal ventilatory and vasopressor support. Ultimately, the patient was made Do Not 121 
Resuscitate and was palliatively extubated on hospital day 4. 122 
Discussion: 123 
These five cases of new-onset DKA in Type 2 diabetics highlight a previously undescribed 124 
presentation of patients with COVID-19. While COVID-19  has not previously been reported as a 125 
precipitant of DKA,  cases of fulminant DKA have been observed with other viral infections, such as 126 
influenza. For example, Moghadami et al described two patients that presented to emergency care in 127 
DKA presumed secondary to H1N1 influenza, both of whom ultimately died.7 It is well known that DKA 128 
has a strong association with activated innate immune cells secondary to infection.2,8 What is unusual 129 
about our cases is the severity of DKA in previously controlled diabetics. Notably, glipizide, a drug 130 
inherently dependent on endogenous pancreatic function, was used for hyperglycemic control in cases 1 131 
and 2. While these patients may have been advancing in their disease, their rapid evolution from DM2 to 132 
DKA suggests a more acute precipitant. This rapid progression, in conjunction with the known cytokine 133 
release of COVID-19,9 raises the possibility that the intense cytokine release associated with COVID-19 134 
may play a role in the insulin dysregulation seen in these patients.10 Another possibility is that these 135 
patients were sustaining pancreatic injury to beta-islet cells, as a recent study has shown a high rate of 136 
pancreatic injury in COVID-19 infection.11  It is important to note that in our case series, all patients had 137 
a relatively high hemoglobin A1c, ranging from 9.5 to 11.9 This may suggest that suboptimal glucose 138 
control predisposes to more severe forms of COVID-19 or to the precipitation of DKA. We also note that 139 
3 of our 5 patients were Hispanic. Although there is no pathophysiologic basis to suspect that Hispanic 140 
patients would be at higher risk for COVID-19 associated DKA, this is notable in that our hospital 141 
population is only approximately 10% Hispanic. Further study is needed to help elucidate risk factors for 142 
the development of DKA among diabetic patients with COVID-19.  143 
Although the definitive pathophysiology behind SARS-CoV-2 acting as a precipitant for DKA in 144 
people with DM2 is unknown, this illness pattern does have important implications. For instance, patients 145 
with DKA often rely on compensatory tachypnea for the regulation of acidosis, but this may be difficult 146 
to manage in COVID-19 patients. Due to aerosolization concerns with COVID-19 and constraints of 147 
negative pressure room supply, many centers are moving away from non-invasive positive pressure 148 
ventilation (NIPPV) and instead utilizing high flow nasal cannula (HFNC) or early intubation strategies. 149 
High flow nasal canula allows providers to either avoid intubation or to optimize preoxygenation for early 150 
intubation and mechanical ventilation.12 This clinical predicament may have contributed to the poor 151 
outcome in Case 5 of our series, as shortly after intubation, the patient spiraled into profound metabolic 152 
acidosis, hemodynamic instability, and ultimately, multi-organ system failure. Another important 153 
implication of co-existing DKA and COVID-19 infection is how to manage fluid balance. Intravenous 154 
crystalloid is a staple in the resuscitation of patients with DKA, but its use has been drawn into question 155 
for patients with COVID-19 pneumonia for fear of worsening respiratory status and oxygenation. Further 156 
studies on the optimal management of concurrent acidosis and respiratory insufficiency from pneumonia 157 
in patients suffering DKA precipitated by COVID-19 would be of great use.  158 
Why should an emergency physician be aware of this? 159 
 In the midst of the current pandemic, COVID-19 infection should be considered as a possible 160 
precipitant in patients with DKA. Minute ventilation matching and judicious fluid resuscitation are 161 
essential to the management of the combined DKA and COVID-19 disease processes. It is paramount to 162 
identify patients in this cohort in order to protect healthcare workers while intervening aggressively to 163 
optimize patient outcomes. 164 
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Figure 1: Features of chest radiograph of selected cases. (A) Case 1, bilateral interstitial 202 
opacifications with endotracheal tube in place. (B) Case 2, mild interstitial prominence of left 203 
lower lobe. (C ) Case 3, clear chest. (D) Case 4, developing right upper and lower interstitial 204 
prominences. (E) Case 5, extensive severe bilateral disease with interstitial and basilar 205 
predominance.  206 
 207 
Table 1: Characteristics of Patients Presenting with Diabetic Ketoacidosis and COVID-19 Infection 
Case 1  2   3  4  5 Average 
Demographics  
Age  55 57 38 45 63 49 
Sex Male Female Male Female Female  
Body Mass Index  31.1 19.8 29.1 21.4 36.2 27.5 
Patient Disease Characteristics  
Diabetes Medications Glipizide 
Metformin, 
Glipizide 
Insulin 
detemir 
and aspart 
None 
              
Insulin 
 
Hemoglobin A1C 9.5  11.3 11.9 15 9.8 11.5 
Presentation Characteristics  
Heart Rate 91 122 129 116 97 114 
Blood Pressure 161/77 128/75 99/68 115/75 150/90 126/74 
Respiratory Rate 55 32 20 18 53 31 
SpO2 66% on NRB 97 99 100 95% on 6L 91 
Glasgow Coma Score 11 15 15 15 15 14 
Initial Glucose 948 227 399 342 749 533 
pH 7.13 7.11 7.02 6.99 7.21  7.06 
Anion Gap 21 24 22 18 18 21 
Beta-hydroxy Butyrate 0.75 9.36 n/o 7.83 n/o 5.98 
COVID-19 Laboratory Values  
      
Creatine kinase 545 n/o n/o n/o 329 437 
C-Reactive Protein >19.0 18.2 n/o n/o >19.0 18.7 
D-dimer 5.44 1.06 n/o n/o >35.2 13.9 
Ferritin 1214 337 n/o n/o >16,500 6,017 
Fibrinogen 600 n/o n/o n/o n/o - 
Lactate Dehydrogenase 931 n/o n/o n/o 3,934 2,433 
Procalcitonin 1.38 0.16 n/o n/o 3.65 1.73 
Troponin n/o <0.02 n/o n/o 2.23 1.13 
Hospitalization Characteristics  
Fluid to gap closure (mL) 2125 4625 3100 5550 6160 3850 
Time to gap closure (minutes) 38 900 194 720 650 463 
       Length of Stay (Days) 
 
8 4 3 4 4.75 
                             Outcome 
Hospitalized at 
time of printing  
Discharge 
home  
 Discharge 
home 
Discharge 
home 
      Death 
 
n/o - not obtained       
*Room air oxygen saturations (SpO2) were not available for all patients 
 
  
